Arbekacin inhalation - Meiji Seika Pharma

Drug Profile

Arbekacin inhalation - Meiji Seika Pharma

Alternative Names: ME-1100

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meiji Seika Pharma
  • Class Aminoglycosides; Antibacterials; Cyclohexanols; Cyclohexylamines; Hexosamines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Nosocomial pneumonia

Most Recent Events

  • 23 Feb 2018 Phase-I development is ongoing in USA (Meiji Seika Pharma pipeline, February 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Nosocomial-pneumonia in USA (Inhalation, Liquid)
  • 22 Apr 2017 Antimicrobial activity data from preclinical studies in Nosocomial pneumonia presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top